of radiation. 4 The grade of mucositis can vary from mild, affecting only limited parts of the mucosa to severe, with ulcers covering large parts of the mucosa. The severe forms can lead to inability to eat and sometimes also to drink.
Some of the aspects of quality of life (QoL) most affected after cancer treatment are dry mouth, dysphagia, trismus, eating problems, and taste loss/change. [5] [6] [7] [8] [9] [10] [11] [12] [13] Several studies have analysed both QoL and the salivary secretion rate. 6, 8, [13] [14] [15] [16] No significant correlations between salivary flow rate (measured from the parotid and submandibular/sublingual glands) and QoL scores at 3, 6, or 12 months post-RT were found by Lin et al 14 Other studies have shown that participants with very low parotid flow rates one year post-RT report more problems with xerostomia compared to subjects with higher flow rates. 6, 8 Patients with the lowest stimulated salivary secretion rates (≤0.2 mL/ min) at a median of 33.5 months post RT reported more symptoms of dyspnoea, swallowing, social eating, and dry mouth compared with those who had a higher salivary secretion rate. 15 In our previous study, patients with a stimulated salivary secretion rate of ≤0.7 mL/ min (usually used as a cut-off for hyposalivation) reported more problems with cognitive functioning, insomnia, swallowing, social eating, dry mouth, and sticky saliva compared with participants with a secretion rate of >0.7 mL/min both at six and 12 months post treatment. 16 Some studies have analysed QoL 24 months or longer after completed treatment. 5, [17] [18] [19] At 36 months post treatment, physical functioning, taste/smell, dry mouth, and sticky saliva were significantly worse compared with baseline while pain, insomnia, speech, emotional functioning, and global QoL was significantly better. 17 At 36 months post RT, improvements regarding mental distress, global
QoL and pain was found compared with pretreatment values. 5 Deteriorations were seen for dry mouth, senses, teeth and mouth opening. 5 When QoL was evaluated at least 24 months post treatment (range 24-110 months) and compared with QoL in the normal population it was found that patients scored worse on emotional and social functioning, overall health-related QoL and fatigue. 18 Patients who reported of severe xerostomia at 24 months post treatment scored worse on overall QoL, physical functioning, role functioning, cognitive functioning, and social functioning, fatigue and insomnia compared with patients with no xerostomia symptoms. 19 The salivary secretion rate was not measured in the studies mentioned above. [17] [18] [19] Also, radiation technique has improved since those studies were performed. It is therefore possible that further improvements in the salivary secretion rate occurs over time improving also QoL.
The aim was to examine QoL for patients with H&N cancer in relation to hyposalivation prior to treatment and at 6, 12, and 24 months after treatment.
| S TUDY P OPUL ATI ON AND ME THODOLOGY
This study is part of a larger project aiming at longitudinally following the oral microflora, stimulated whole and minor gland salivary secretion rates and composition, diet and QoL in subjects undergoing treatment for H&N cancer. The project has been approved by the Regional Ethical Committee at the University of Gothenburg (Dnr 682-07). QoL data pretreatment and at six and 12 months post treatment has been published previously. 16 In the present study, QoL data from 24 months post treatment has been added. 
| Oncological treatment
The oncological treatment was given at Sahlgrenska University Hospital, Gothenburg. All patients received curative RT. The patients with tonsil cancer received bilateral RT. Chemotherapy was generally given as two cycles of cisplatin and 5-fluorouracil.
The patients underwent oral examinations and determinations of the stimulated salivary secretion before treatment and 6, 12, and 24 months after completed RT. All examinations and saliva measurements were performed by the author BFM between nine am and noon.
| Stimulated whole salivary secretion rate
The patients were instructed to avoid eating, drinking (except water), tooth-brushing, and smoking for one hour before their appointment. The stimulated whole salivary secretion rate was determined using paraffin wax. The patient was instructed to chew on a piece of paraffin until it was soft and to swallow once.
Thereafter the patient chewed on the paraffin wax at his/her own pace and all saliva produced was collected in a test tube during three minutes.
| Quality of Life Questionnaires
The 
| Statistical methods
The related-samples Wilcoxon signed rank test was used to analyse differences in the stimulated salivary secretion rate between the different time-points. Six, 12, and 24 months post-RT, the participants were divided into two groups regarding their stimulated whole salivary secretion rate; ≤0.7 mL/min (hyposalivation) and >0.7 mL/min.
Mean values were calculated as well as 95% confidence intervals.
Group differences >10 points on the EORTC scales or single items were regarded as clinically significant differences. 23 Differences in QoL between salivary flow groups above or below the cut-off for stimulated whole salivary secretion rate, 0.7 mL/min, at 6, 12, and
24 months post treatment were tested with the Mann-Whitney U test with a level of significance set at 5%. Because of the multiple statistical comparisons, results should be interpreted cautiously.
| RE SULTS

| Patients
The mean age was 59 ± 8 years (median 58 years). Nineteen of the patients were men and 10 were women. The most common diagnosis was tonsil cancer (n = 16, 55%), followed by tongue base cancer (n = 6, 21%). Twenty-three (79%) of the patients received intensity-modulated radiotherapy (IMRT). Nineteen patients (66%) received concomitant chemotherapy.
| Stimulated salivary secretion rate
The mean stimulated salivary secretion rates are presented in Table 1 .
The proportion of patients with a secretion rate of <0.7 mL/min decreased over time from 72% at 6 months post RT to 50% at 24 months follow-up. No statistically significant improvement in mean secretion rate was seen at 24 months compared with 12 months post-RT. At 24 months post-RT, the mean stimulated salivary secretion rate was still lower compared with pretreatment (P < 0.001).
| EORTC C30 compared with the normal population
For five of 15 functioning/symptom scales and single items on the EORTC C30 clinically significant differences (ie, a difference ∆ >10
points) compared with the normal population 26 were found (Table 2) ; The group with hyposalivation scored worse (clinically significant differences) on three functioning/symptom scales and single items at both six and 12 months post RT and for two functioning/symptom scales and single items at 24 months post RT. At all three time-points more problems with insomnia were reported. For the group with a secretion rate of >0.7 mL/min no clinically significant differences compared with the normal population were detected at 24 months post RT (Table 2 ).
| EORTC C30
The group with hyposalivation compared with the group with a secretion rate of >0.7 mL/min Clinically significant differences were detected for four functioning/symptom scales and single items at six months and for (17) 2 (7) 2 (7) ≤0.7 mL/min 2 (7) 16 (55) 14 (48) 12 (43) >0.7 mL/min 27 (93) 8 (28) 13 (45) 14 (50) a Significantly lower compared with pretreatment (P < 0.001).
b Significantly higher compared with 6 months post treatment (P < 0.001).
TA B L E 1 Stimulated whole salivary secretion rate (mL/min) for the patients pretreatment and 6, 12, and 24 months after completed RT TA B L E 2 Changes in EORTC QLQ C30 during two years of follow-up, mean value and 95% confidence interval (CI) for H&N cancer patients with a stimulated salivary secretion rate ≤0.7 mL/min or >0.7 mL/min Clinically significant difference (>10 points) according to secretion rate (≤0.7 mL/min and >0.7 mL/min) (bold+italic). (Table 2) . For insomnia clinically significant differences were detected at all three time-points. At 12 months, the differences for emotional functioning and insomnia were statistically significant (P < 0.05) and at 24 months the difference for fatigue (P < 0.05). High scores for a symptom scale/item represent high levels of symptoms. Scale from 0-100, where 100 represents maximal level of symptoms and 0 means no symptoms at all. a Clinically significant difference (>10 points) compared with normal population (bold). b Clinically significant difference (>10 points) according to secretion rate (≤0.7 mL/min and >0. 7 mL/min) (bold+italic). c Statistically significant differences (P < 0.05, Mann-Whitney U test). * Normal population obtained from Hammerlid et al 27 
TA B L E 3 Changes in EORTC QLQ
| EORTC HN35 compared with the normal population
Pretreatment, clinically significant differences were detected for pain (∆ 18.9 points), swallowing (∆ 13.6 points), and problems with mouth opening (∆ 10.6 points) compared with the normal population 27 (Table 3) . Clinically significant differences were detected for 10 of the symptom scales and single items on the EORTC HN35 both at 6 months and at 24 months post-RT for the group with hyposalivation, while an improvement was seen over time for the group with a secretion rate of >0.7 mL/min, nine at six months and four at 24 months post RT (Table 3) 
| EORTC HN35 The group with hyposalivation compared with the group with a secretion rate of >0.7 mL/min
For the group with hyposalivation the number of clinically significant differences increased over time, from seven and six at the 6 and 12 months follow up, respectively, to nine symptom scales and single items at the 24 months follow-up. At all three time-points more problems with swallowing, social eating, dry mouth, and sticky saliva were reported by the group with hyposalivation. The largest difference was seen for sticky saliva (37.7 points) and this difference was also statistically significant at both 12 and 24 months (P < 0.05 and P < 0.01, respectively). A clinically significant difference reported at both 12 and 24 months was more problems with sexuality (∆ 21.6 and ∆ 16.3 points, respectively). Other symptoms reported at 24 months were coughing (∆ 16.7 points), problems with mouth opening (∆ 16.6 points), pain (∆ 15.5 points), senses (∆ 13.1 points).
Regarding "senses" more problems with taste than with smell was reported; four patients reported "quite a bit" and one patient "a lot", while "not at all" or "sometimes" was reported for smell.
| HADS
The largest differences between the hyposalivation group and the group with a secretion rate >0.7 mL/min regarding scores indicating possible or probable anxiety or depression were seen at 12 months post RT (Table 4) . At the 24 months follow-up two patients (one man and one woman) with a secretion rate of ≤0.7 mL/min and one patient (woman) with a secretion rate of 0.9 mL/min had scores indicating probable anxiety and two of them possible or probable depression. All these three patients showed scores indicating possible or probable anxiety and/or depression also pretreatment and at 6 and 12 months post-RT.
| D ISCUSS I ON
The stimulated salivary flow rate and QoL was examined up to two years after treatment for H&N cancer. At 24 months, the group with hyposalivation experienced worse functioning and more symptoms compared to those with higher secretion rates, with more symptoms related to the amount of saliva (clinically significant differences, ie,>10 points) and the symptoms seemed to have worsened at 24 months compared with 12 months.
The group with a secretion rate of >0.7 mL/min showed improvements over time with a decreasing number of functioning scales, symptom scales, and single items scoring worse compared with the normal population. At 24 months these patients reported more problems with swallowing, senses, dry mouth, and sticky saliva. This underlines the importance of regaining a salivary flow rate >0.7 mL/min, which might contribute to improved functions after treatment for cancer in the head and neck region.
In the present study, patients with hyposalivation reported problems with social eating. Problems with eating have been found also in other studies. 28, 29 Saliva has several important functions in the oral cavity, for example when eating. The watery saliva that is produced by the parotid glands at chewing helps to soften food and contribute to bolus formation. Within 1 and 2 years post treatment, most patients had regained the ability to consume foods and drinks but often with difficulty. 29 Due to eating impairment, the patients TA B L E 4 Proportion of patients exceeding cut-off values for HAD anxiety and depression (≥8) among those with stimulated whole salivary secretion rates ≤0.7 mL/min vs >0.7 mL/min did not enjoy meals and many avoided eating and drinking in public, as they felt embarrassed and less self-confident when eating with friends or colleagues. 29 Other difficulties at meals were that it took longer time and it was important to choose foods with the right consistency. 29 In the study by Dirix et al, 28 patients filled in a questionnaire about their problems and symptoms 6-156 months post RT (mean 35.7 months). Forty-five % of the patients reported that they were restricted regarding the amount and type of food they ate (Quite a lot, very much), about one third reported that it was awkward to eat in front of other people.
Problems with swallowing and sticky saliva were reported in the present study and especially by the patients in the hyposalivation group. In a study by Vainshtein et al, 30 worse results on the swallowing performance status scale was correlated with lower stimulated salivary secretion rate. Besides from the lower amount of fluid it is likely that the saliva composition has been altered with for example a reduced concentration of mucins, which have the ability to moisten and protect the mucosal membranes and also aids swallowing. 31 A lower concentration of mucin MUC5B in patients who complained of severe xerostomia than in patients with mild or no xerostomia problems has been found at 12 months post RT. 32 It is the clinical experience that patients with hyposalivation report that products available for relieving dry mouth problems are not so effective or have short- Another important function saliva has is to dissolve flavouring substances and it is therefore important for the sense of taste. At the 24 months follow-up, the group with hyposalivation reported more problems with senses and especially for taste. This is in congruence with the findings in questionnaire studies. 28, 34 Sixty-three % complained of taste loss and 40% reported that their food tasted less or had a different taste. 28 In the study by Rose-Ped et al 34 90%
reported changes in taste. Furthermore, 54% percent reported complete loss of taste, 33% distorted taste and 13% reduced taste. 34 Problems with taste might further aggravate the problems with eating and especially social eating for the patients.
At 6, 12, and 24 months post RT, the group with hyposalivation scored worse for insomnia and at 12 and 24 months they scored worse for fatigue. This is in congruence with Spratt et al 35 who found that 50% of patients who had undergone treatment for oropharyngeal cancer reported that they were more tired compared with pretreatment at 24 months post RT. No data regarding salivary secretion rate is given in the study by Spratt et al 35 It is possible that the low salivary secretion leads to frequent awakenings during the night and the need to drink water to relief dry mouth feelings.
To wake up several times per night might lead to fatigue during the day. It might also be worries about the future and low prospects of getting better, which disturbs sleep.
Anxiety problems were still present in 21% of the patients with secretion rates of ≤0.7 mL/min at 24 months post RT. It has been
shown that more than 50% of patients who had undergone treatment for cancer had unmet survivorship needs like fear of cancer recurrence, future uncertainty, sadness, and concerns about family/ friends. 36 An 8-week interdisciplinary rehabilitation programme for patients with head and neck cancer focusing on nutrition, exercise, fatigue management and coping strategies lead to a clinically meaningful decrease in the severity of many symptoms, ie pain, weakness, insomnia, and depression, improvement in nutritional status, physical function and quality of life. 37 Although more problems were reported in several areas 24 months post-RT there were also several functioning and symptom scales such as for example physical and cognitive functioning and dyspnoea for which the patients scored similar to the normal population. 26, 27 This might be due to patients adjusting their perception of pretreatment health-related quality of life (HRQoL) and their judgement of acceptable HRQoL as a result of their disease and treatment experience. 38 Patients grow accustomed to their new life and perceive it to be normal. Common coping strategies in patients ≥6 months post treatment were active coping (trying to do something about the situation), acceptance, and religion. 39 When an individual undergoes changes in life such as for example being diagnosed with a serious disease and undergoing a demanding treatment, there are many psychological aspects that affect the situation and the behaviour of the individual and this in turn, affects the individual's ability to rehabilitate. "Self-efficacy" is a part of the social cognitive theory and describes an individual's beliefs in his or her ability to handle a particular situation or event that affects his/her life. 40 Previous studies have shown that people with high self-efficacy have a more positive health related behaviour regarding both oral and general health, compared to people with lower self-efficacy. 41, 42 Positive relationship between high self-efficacy, health behaviour, and QoL in cancer patients was demonstrated in a study by Omran & Mcmillan. 43 The relation between self-efficacy and QoL among patients with H&N cancer will be further studied in future research from our group.
In conclusion, patients with a hyposalivation (≤0.7 mL/min) tended to show deterioration in health related QoL functions at 24 months post RT compared with 12 months post-RT. Most pronounced were problems with insomnia, swallowing, social eating, dry mouth, and sticky saliva.
| CLINI C AL RELE VAN CE
| Scientific rationale
It could be assumed that hyposalivation as a consequence of radiation therapy in the head and neck region affects quality of life.
| Principal findings
Two years post treatment, participants with hyposalivation reported more problems with insomnia, swallowing, social eating, dry mouth, and sticky saliva, compared with those with secretion rates >0.7 mL/ min.
| Practical implications
It is important for dental and health care personal to acknowledge the negative effects of hyposalivation on quality of life and the patients' need for professional advice and support also years after completed treatment for cancer in the head and neck region.
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